Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein

Hybridoma

Volumn 17, Issue 2, 1998, Pages 191-198

  Rauscher III, Frank J ^a   Morris, Jennifer F ^b   Fredericks, William J ^c   Lopez Guisa, Jesus ^d   Balakrishnan, Christopher ^a   Jost, Monika ^a   Herlyn, Meenhard ^a   Rodeck, Ulrich ^a,e,f  

^a WISTAR INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ONYX PHARMACEUTICALS   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; EMBRYO DEVELOPMENT; EPITOPE MAPPING; GENE DELETION; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RNA SPLICING; TUMOR SUPPRESSOR GENE;

ANIMALIA; MURINAE; ORYCTOLAGUS CUNICULUS;

EID: 0031805732     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.191     Document Type: Article

References (26)

1. Coppes MJ, and Williams BR: The molecular genetics of Wilms tumor. Cancer Invest 1994;12:57-65.
2. Koo HP, and Hensle TW: Molecular biology of Wilms' tumor. Urol Clin North Am 1993;20:323-331.
3. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, and Housman DE: An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990;61:1257-1269.
4. Rauscher JF III: The WT1 Wilms' tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 1993;7:896-903.
5. Ryan G, Steele-Perkins V, Morris JF, Rauscher FJ III, and Dressier GR: Repression of Pax-2 by WT1 during normal kidney development. Development 1995;121:867-875.
6. Kreidberg JA: Gene targeting in kidney development. Med Pediatr Oncol 1996;27:445-452.
7. Haber DA, Englert C, and Maheswaran S: Functional properties of WT1. Med Pediatr Oncol 1996;27:453-455.
8. Little M, and Wells C: A clinical overview of WT1 gene mutations. Human Mutat 1997;9:209-225.
9. Amin KM, Litzky LA, Smythe WR, Mooney AM, Morris JM, Mews DJ, Pass HI, Kari C, Rodeck U, Rauscher FJ III, Kaiser LR, and Albelda SM: Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-356.
10. Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, Van Boreckhoven C, and Van Marck E: WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997;181:67-74.
11. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, and Thiel R: Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-1067.
12. Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, and Thiel E: Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 1997;70:518-523.
13. Dressler GR: Transcription factors in renal development: The WT1 and Pax-2 story. Semin Nephrol 1995;15:263-271.
14. Morris JF, Madden SL, Toumay OE, Cook DM, Sukhatme VP, and Rauscher FJ III: Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus. Oncogene 1991;6:2339-2348.
15. Zhou J, Rauscher FJ III, and Bondy C: Wilms' tumor (WT1) gene expression in rat decidual differentiation. Differentiation 1993;54: 109-114.
16. Yeger H, Forget D, Alami J, Williams BR: Analysis of WT1 gene expression during mouse nephrogenesis in organ culture. In Vitro Cell Dev Biol Anim 1996;32:496-504.
17. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G, Griffin J, Minden M, Housman DE, and Haber DA: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nature Genet 1993;4:415-420.
18. Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA, and Garvin AJ: WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 1993;262:2057-2059.
19. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V, and Hastie ND: Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995;81: 391-4011.
20. Lamond AI: RNA processing. Wilms' tumour - the splicing connection? Curr Biol 1995;5:862-865.
21. Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D, and Pelletier J: Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993;11:393-399.
22. Miwa H, Beran M, and Saunders GF: Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-409.
23. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, and Miyoshi I: Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 1993;7:970-977.
24. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakandi H, Ishidate T, Akiyama T, and Kishimoto T: WT1 as a new prognostic factor and a new marker for the detectionof minimal residual disease in acute leukemia. Blood 1994;84:3071-3079.
25. Rodeck U, Bossier A, Kari C, Humphreys CW, Györfi T, Maurer J, Thiel E, and Menssen HD: Expression of the Wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994;59:78-82.
26. Silberstein GB, Van Horn K, Strickland P, Roberts CT, Jr, and Daniel CW: Altered expression of the WT1 Wilms' tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997;94:8132-8137.